Cargando…
Pre-exposure Prophylaxis Recent Adherence With Real-Time Adherence Feedback and Partner Human Immunodeficiency Virus Self-Testing: A Pilot Trial Among Postpartum Women
BACKGROUND: Pre-exposure prophylaxis (PrEP) is safe and effective in postpartum women. Human immunodeficiency virus self-testing (HIVST) for male partners combined with biofeedback counseling through real-time adherence measures may improve PrEP use among postpartum women. METHODS: Between August 20...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8794072/ https://www.ncbi.nlm.nih.gov/pubmed/35097151 http://dx.doi.org/10.1093/ofid/ofab609 |
_version_ | 1784640745473310720 |
---|---|
author | Joseph Davey, Dvora Leah Dovel, Kathryn Mvududu, Rufaro Nyemba, Dorothy Mashele, Nyiko Bekker, Linda-Gail Gorbach, Pamina M Coates, Thomas J Myer, Landon |
author_facet | Joseph Davey, Dvora Leah Dovel, Kathryn Mvududu, Rufaro Nyemba, Dorothy Mashele, Nyiko Bekker, Linda-Gail Gorbach, Pamina M Coates, Thomas J Myer, Landon |
author_sort | Joseph Davey, Dvora Leah |
collection | PubMed |
description | BACKGROUND: Pre-exposure prophylaxis (PrEP) is safe and effective in postpartum women. Human immunodeficiency virus self-testing (HIVST) for male partners combined with biofeedback counseling through real-time adherence measures may improve PrEP use among postpartum women. METHODS: Between August 2020 and April 2021, we randomized postpartum women who initiated PrEP in pregnancy 1:1 to the intervention group (HIVST + biofeedback counseling after urine tenofovir test) or to standard of care ([SOC] facility-based human immunodeficiency virus [HIV] tests and routine counseling without biofeedback). The outcomes of interest were PrEP adherence in the past 48–72 hours via urine tenofovir tests and partner HIV testing, measured 1-month after randomization. Secondary outcomes included the proportion of partners who tested for HIV and the discrepancy between self-reported PrEP adherence and urine tenofovir result. RESULTS: We enrolled 106 women (median age = 26 years). At enrollment, 72% of women reported missing <2 doses in the past 7 days; 36% of women had tenofovir present in her urine. One month after enrollment, 62% (n = 33) of women in the intervention arm had tenofovir present in their urine compared to 34% (n = 18) in SOC (risk ratio [RR] = 1.83; 95% confidence interval [CI] = 1.19–2.82; P = .001). Two thirds of women in the intervention arm reported that her partner tested for HIV (66%; n = 35), compared to 17% (n = 9) in SOC (RR = 3.89; 95% CI = 2.08–7.27; P < .001). Self-reported PrEP adherence (took PrEP >5 of last week) with no tenofovir in urine test was lower in the intervention group (17% vs 46%; RR = 0.33; 95% CI = 0.17–0.67; P = .03). No social or clinical adverse events were reported in the intervention arm. CONCLUSIONS: The HIVST for partners and biofeedback counseling increased levels of recent PrEP adherence, pointing to the importance of these interventions to support PrEP use in this population. |
format | Online Article Text |
id | pubmed-8794072 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-87940722022-01-28 Pre-exposure Prophylaxis Recent Adherence With Real-Time Adherence Feedback and Partner Human Immunodeficiency Virus Self-Testing: A Pilot Trial Among Postpartum Women Joseph Davey, Dvora Leah Dovel, Kathryn Mvududu, Rufaro Nyemba, Dorothy Mashele, Nyiko Bekker, Linda-Gail Gorbach, Pamina M Coates, Thomas J Myer, Landon Open Forum Infect Dis Major Article BACKGROUND: Pre-exposure prophylaxis (PrEP) is safe and effective in postpartum women. Human immunodeficiency virus self-testing (HIVST) for male partners combined with biofeedback counseling through real-time adherence measures may improve PrEP use among postpartum women. METHODS: Between August 2020 and April 2021, we randomized postpartum women who initiated PrEP in pregnancy 1:1 to the intervention group (HIVST + biofeedback counseling after urine tenofovir test) or to standard of care ([SOC] facility-based human immunodeficiency virus [HIV] tests and routine counseling without biofeedback). The outcomes of interest were PrEP adherence in the past 48–72 hours via urine tenofovir tests and partner HIV testing, measured 1-month after randomization. Secondary outcomes included the proportion of partners who tested for HIV and the discrepancy between self-reported PrEP adherence and urine tenofovir result. RESULTS: We enrolled 106 women (median age = 26 years). At enrollment, 72% of women reported missing <2 doses in the past 7 days; 36% of women had tenofovir present in her urine. One month after enrollment, 62% (n = 33) of women in the intervention arm had tenofovir present in their urine compared to 34% (n = 18) in SOC (risk ratio [RR] = 1.83; 95% confidence interval [CI] = 1.19–2.82; P = .001). Two thirds of women in the intervention arm reported that her partner tested for HIV (66%; n = 35), compared to 17% (n = 9) in SOC (RR = 3.89; 95% CI = 2.08–7.27; P < .001). Self-reported PrEP adherence (took PrEP >5 of last week) with no tenofovir in urine test was lower in the intervention group (17% vs 46%; RR = 0.33; 95% CI = 0.17–0.67; P = .03). No social or clinical adverse events were reported in the intervention arm. CONCLUSIONS: The HIVST for partners and biofeedback counseling increased levels of recent PrEP adherence, pointing to the importance of these interventions to support PrEP use in this population. Oxford University Press 2021-12-23 /pmc/articles/PMC8794072/ /pubmed/35097151 http://dx.doi.org/10.1093/ofid/ofab609 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Major Article Joseph Davey, Dvora Leah Dovel, Kathryn Mvududu, Rufaro Nyemba, Dorothy Mashele, Nyiko Bekker, Linda-Gail Gorbach, Pamina M Coates, Thomas J Myer, Landon Pre-exposure Prophylaxis Recent Adherence With Real-Time Adherence Feedback and Partner Human Immunodeficiency Virus Self-Testing: A Pilot Trial Among Postpartum Women |
title | Pre-exposure Prophylaxis Recent Adherence With Real-Time Adherence Feedback and Partner Human Immunodeficiency Virus Self-Testing: A Pilot Trial Among Postpartum Women |
title_full | Pre-exposure Prophylaxis Recent Adherence With Real-Time Adherence Feedback and Partner Human Immunodeficiency Virus Self-Testing: A Pilot Trial Among Postpartum Women |
title_fullStr | Pre-exposure Prophylaxis Recent Adherence With Real-Time Adherence Feedback and Partner Human Immunodeficiency Virus Self-Testing: A Pilot Trial Among Postpartum Women |
title_full_unstemmed | Pre-exposure Prophylaxis Recent Adherence With Real-Time Adherence Feedback and Partner Human Immunodeficiency Virus Self-Testing: A Pilot Trial Among Postpartum Women |
title_short | Pre-exposure Prophylaxis Recent Adherence With Real-Time Adherence Feedback and Partner Human Immunodeficiency Virus Self-Testing: A Pilot Trial Among Postpartum Women |
title_sort | pre-exposure prophylaxis recent adherence with real-time adherence feedback and partner human immunodeficiency virus self-testing: a pilot trial among postpartum women |
topic | Major Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8794072/ https://www.ncbi.nlm.nih.gov/pubmed/35097151 http://dx.doi.org/10.1093/ofid/ofab609 |
work_keys_str_mv | AT josephdaveydvoraleah preexposureprophylaxisrecentadherencewithrealtimeadherencefeedbackandpartnerhumanimmunodeficiencyvirusselftestingapilottrialamongpostpartumwomen AT dovelkathryn preexposureprophylaxisrecentadherencewithrealtimeadherencefeedbackandpartnerhumanimmunodeficiencyvirusselftestingapilottrialamongpostpartumwomen AT mvududurufaro preexposureprophylaxisrecentadherencewithrealtimeadherencefeedbackandpartnerhumanimmunodeficiencyvirusselftestingapilottrialamongpostpartumwomen AT nyembadorothy preexposureprophylaxisrecentadherencewithrealtimeadherencefeedbackandpartnerhumanimmunodeficiencyvirusselftestingapilottrialamongpostpartumwomen AT mashelenyiko preexposureprophylaxisrecentadherencewithrealtimeadherencefeedbackandpartnerhumanimmunodeficiencyvirusselftestingapilottrialamongpostpartumwomen AT bekkerlindagail preexposureprophylaxisrecentadherencewithrealtimeadherencefeedbackandpartnerhumanimmunodeficiencyvirusselftestingapilottrialamongpostpartumwomen AT gorbachpaminam preexposureprophylaxisrecentadherencewithrealtimeadherencefeedbackandpartnerhumanimmunodeficiencyvirusselftestingapilottrialamongpostpartumwomen AT coatesthomasj preexposureprophylaxisrecentadherencewithrealtimeadherencefeedbackandpartnerhumanimmunodeficiencyvirusselftestingapilottrialamongpostpartumwomen AT myerlandon preexposureprophylaxisrecentadherencewithrealtimeadherencefeedbackandpartnerhumanimmunodeficiencyvirusselftestingapilottrialamongpostpartumwomen |